Colorectal Cancer Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The report covers Colorectal Cancer Therapeutics Market and the Market is Segmented by Therapy (Immunotherapy, Chemotherapy, and Others), by End User (Hospital, Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market provides the value (in USD million) for the above-mentioned segments.

Colorectal Cancer Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Colorectal Cancer Therapeutics Market Size

Colorectal Cancer Therapeutics Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
CAGR 6.10 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Colorectal Cancer Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Colorectal Cancer Therapeutics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Colorectal Cancer Therapeutics Market Analysis

The Global Colorectal Cancer Therapeutics Market is expected to register a CAGR of 6.1% during the forecast period.

Cancer care and maintaining high standards of diagnosis and treatment are top priorities for national health authorities and international health systems around the world. However, the pandemic has shifted that focus away from oncology services. Colorectal cancer patients are particularly vulnerable to disruptions in their care, as endoscopy diagnostics have been stopped due to concerns about viral transmission. Thus, due to the delay in diagnosis COVID-19 had an impact on the colorectal cancer therapeutics market. Various studies have been published on the impact of COVID. For example, a research study published in November 2021 titled "Impact of the COVID-19 pandemic on the diagnosis and treatment of colorectal cancer: a systematic review" stated that the reduction in the diagnosis and treatment of colorectal cancer due to the COVID-19 pandemic, offsetting the reduction and preventing the continuation of this downward trend, it requires serious and effective interventions to prevent its subsequent consequences, including referral of people with advanced stages and urgent conditions, increased treatment costs and reduced quality of life and patient survival. However, the market is likely to grow in the coming future.

The rise in the prevalence of colorectal cancer is one of the key factors driving the growth of the market. According to statistics published by GLOBOCAN, colorectal cancer (CRC) is the fourth most common cause of cancer in the German population, and approximately 57,528 new cases of CRC are reported in Germany in 2020. Additionally, according to statistics provided by GLOBOCAN 2020, approximately 33,815 new cases of colon cancer and 11,951 new deaths are reported in the United Kingdom in 2020. Government initiatives have emerged in the UK to diagnose CRC cases in the population aged 50 and over, as this group has a higher incidence. More than 2,000 lives a year can be saved in the United Kingdom with the right diagnosis. In addition, according to statistics provided by GLOBOCAN, there are approximately 306,078 new cases of colon cancer reported in China for the year 2020. It also reported that the five-year prevalence of colon cancer in China is around 749,096. Product launches are another factor in the growth of the market. For example, in July 2020, Taiho Pharmaceutical Co., Ltd. launched its anticancer drug LONSURF (brand in Japan, trifluridine/tipiracil (FTD/TPI), development code TAS-102) for the treatment of patients with metastatic colorectal cancer (mCRC). Lonsurf was approved in China in August 2019 based on the results of the phase III TERRA study in patients with refractory mCRC in Asia (China, South Korea, and Thailand). Such approvals are expected to boost market growth.

However, high costs and the side effects associated with drugs are likely to hinder the market growth.

Colorectal Cancer Therapeutics Industry Overview

The market is partially fragmented and consists of several major players. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known including Amgen Inc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., and F. Hoffmann-La Roche Ltd among others.

Colorectal Cancer Therapeutics Market Leaders

  1. Amgen Inc

  2. Bristol-Myers Squibb Company

  3. Pfizer Inc

  4. F. Hoffmann-La Roche Ltd

  5. Bayer AG

  6. *Disclaimer: Major Players sorted in no particular order
Colorectal Cancer Therapeutics Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Colorectal Cancer Therapeutics Market News

  • In April 2022, the United States Food and Drug Administration approved the third biosimilar for the monoclonal antibody bevacizumab-bevacizumab-maly (Alymsys)-for the treatment of subsets of patients with colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer.
  • In March 2022, Chugai Pharmaceutical Co., Ltd. obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for the anti-HER2 humanized monoclonal antibodies, Perjeta for intravenous infusion, and Herceptin for intravenous infusion, for the additional indication of advanced or recurrent HER2-positive colon cancer or rectal cancer not amenable to curative resection that has progressed after cancer chemotherapy.

Colorectal Cancer Therapeutics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence and Prevalence of Colorectal Cancer
    • 4.2.2 Technological Advancements in Radiology and Chemotherapy
  • 4.3 Market Restraints
    • 4.3.1 High Costs and the Side Effects Associated with Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Therapy
    • 5.1.1 Immunotherapy
    • 5.1.2 Chemotherapy
    • 5.1.3 Others
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Clinics
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc
    • 6.1.2 Bayer AG
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 Celleron Therapeutics
    • 6.1.5 Eli Lilly
    • 6.1.6 F. Hoffmann-La Roche Ltd
    • 6.1.7 Pfizer Inc.
    • 6.1.8 Sanofi
    • 6.1.9 Sumitomo Pharma Co., Ltd
    • 6.1.10 TAIHO PHARMACEUTICAL CO., LTD
    • 6.1.11 Takeda Pharmaceutical Company Limited
    • 6.1.12 Teva Pharmaceutical Industries Ltd.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Colorectal Cancer Therapeutics Industry Segmentation

As per the scope of this report, colorectal cancer (CRC) is known as bowel cancer and colon cancer. It is the development of cancer from the colon or rectum. Colorectal cancer (CRC) therapeutics use drugs and various medical devices for cancer treatment. The Colorectal Cancer Therapeutics Market is Segmented by Therapy (Immunotherapy, Chemotherapy, and Others), by End User (Hospital, Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Therapy Immunotherapy
Chemotherapy
Others
By End User Hospitals
Clinics
Others
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Colorectal Cancer Therapeutics Market Research FAQs

What is the current Global Colorectal Cancer Therapeutics Market size?

The Global Colorectal Cancer Therapeutics Market is projected to register a CAGR of 6.1% during the forecast period (2025-2030)

Who are the key players in Global Colorectal Cancer Therapeutics Market?

Amgen Inc, Bristol-Myers Squibb Company, Pfizer Inc, F. Hoffmann-La Roche Ltd and Bayer AG are the major companies operating in the Global Colorectal Cancer Therapeutics Market.

Which is the fastest growing region in Global Colorectal Cancer Therapeutics Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Colorectal Cancer Therapeutics Market?

In 2025, the North America accounts for the largest market share in Global Colorectal Cancer Therapeutics Market.

What years does this Global Colorectal Cancer Therapeutics Market cover?

The report covers the Global Colorectal Cancer Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Colorectal Cancer Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Colorectal Cancer Therapeutics Industry Report

Statistics for the 2025 Global Colorectal Cancer Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Colorectal Cancer Therapeutics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.